Deep-learning ECG to detect pulmonary hypertension
Official title: A Deep-Learning-Enabled Electrocardiogram for Detecting Pulmonary Hypertension: A Randomized Controlled Trial
Run by National Defense Medical Center, Taiwan · NCT07079592 · Data updated 2026-11-12
This trial tests whether an AI-powered ECG can spot high blood pressure in the lungs (pulmonary hypertension) in adults aged 50–85 who have had a recent ECG.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 50 Years to 85 Years |
| Sex | All |
| Enrollment | 8666 (estimated) |
| Sponsor | National Defense Medical Center, Taiwan Academic / other |
| Locations | 1 site (Taipei) |
| Status | Recruiting |
| Started | February 2026 |
| Main results expected | June 15, 2026 |
| Study ends | June 15, 2026 |
| Registry record updated | February 24, 2026 |
| Trial ID | NCT07079592 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults 50–85 years old who have had at least one 12‑lead ECG within the last three months and do not have a prior diagnosis of pulmonary hypertension, excluded cardiomyopathies, or prior heart/lung transplants.
✕Probably not a fit
Patients with an existing diagnosis of pulmonary hypertension, certain cardiomyopathies, prior heart or lung transplants, very high previously measured pulmonary pressures, or without a recent ECG are unlikely to benefit from this screening approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study applies a deep-learning algorithm to routine 12-lead ECGs to screen for elevated pulmonary arterial pressure in older adults. Participants aged 50–85 with a 12-lead ECG within the prior three months will have the AI-ECG analyzed to identify likely elevated PAP. Those flagged by the algorithm would be prompted to undergo echocardiography for confirmation and potential clinical follow-up. The protocol excludes patients with known pulmonary hypertension, certain cardiomyopathies, prior heart or lung transplants, or very high prior echocardiographic pressures to focus on undiagnosed or high-risk cases.
Why it matters
Potential benefit: If successful, this approach could enable earlier, noninvasive detection of pulmonary hypertension and lead to faster diagnostic workups and potentially better outcomes.
How similar studies have gone: Earlier reports have shown promising results for AI-ECG algorithms in detecting elevated pulmonary arterial pressure and predicting cardiovascular outcomes, but broader validation is still limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men or women, ≥ 50 to 85 years of age * At least one 12-lead ECG within 3 months Exclusion Criteria: * A diagnosis of PH WHO Groups 1, 2, 3, 4, or 5 * A diagnosis of hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, cardiac amyloidosis, or infiltrative cardiomyopathy * Prior heart, lung, or heart-lung transplants * Any systolic pulmonary artery pressure \>50 mmHg by echocardiography before * Echocardiography in 3 months before index ECG
Where it's running
-
National Defense Medical Center
Taipei, Taiwan Recruiting
Study contacts
- Study coordinator: Chin Lin, Associate Professor
- Email: up6fup0629@gmail.com
- Phone: 886+2-87923311
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Does AI-based cephalometric tracing match digital manual tracing for orthodontic measurements?
This study tests whether AI-powered cephalometric analysis can produce measurements similar to traditional digital tracing in 100 patient radiographs.
-
Heart score calculator test using GPT-4o and Claude in chest pain patients
This study tests whether two large language models can calculate HEART scores from patient notes and predict 30-day adverse heart events in adults with chest pain in the emergency department.
-
Multi-center artificial intelligence-based quantitative echocardiography evaluation
This project will test whether AI can automatically and accurately measure heart chamber sizes, volumes, and function from echocardiograms in adults with common cardiovascular conditions.
-
AI-assisted whole-course management for safe medicine use in advanced solid tumors
A real-world study compares a smartphone-based digital management system with usual care to see if it reduces drug-related problems and healthcare needs for adults with advanced solid tumors receiving cancer therapy.
-
AI-assisted and traditional workflows for admission diagnosis and management planning
This trial tests whether an AI-agent workflow helps doctors make better admission diagnoses and care plans on simulated cases, compared with plain AI-assisted and traditional workflows.
-
Prediction score for death or lung transplant in emphysema caused by alpha-1 antitrypsin deficiency
This study tests a new prediction tool to identify people with emphysema due to alpha-1-antitrypsin deficiency who are at high risk of death or needing a lung transplant.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.